Havemeyer Place LP Takes $2.81 Million Position in Boston Scientific Corporation $BSX

07 Jun 2026, 07:52 by Teresa Graham · The Cerbat Gem

Havemeyer Place LP purchased a new stake in Boston Scientific Corporation (NYSE:BSX – Free Report) in the 4th quarter, Holdings Channel reports. The fund purchased 29,426 shares of the medical equipment provider’s stock, valued at approximately $2,806,000. Boston Scientific makes up 0.6% of Havemeyer Place LP’s holdings, making the stock its 25th biggest position.

Several other hedge funds have also modified their holdings of BSX. Murphy & Mullick Capital Management Corp lifted its holdings in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares during the period. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $26,000. Colonial Trust Co SC lifted its holdings in shares of Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 231 shares during the period. Bangor Savings Bank lifted its holdings in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the period. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $29,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BSX has been the subject of several recent analyst reports. Stifel Nicolaus set a $75.00 price target on Boston Scientific in a report on Wednesday, May 27th. Needham & Company LLC reissued a “buy” rating and issued a $77.00 price target on shares of Boston Scientific in a report on Monday, May 18th. Raymond James Financial reissued an “outperform” rating and issued a $88.00 price target (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Mizuho reduced their price target on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a report on Monday, April 13th. Finally, Wolfe Research cut Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $85.92.

View Our Latest Report on Boston Scientific

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

Positive Sentiment: Canaccord reiterated a Buy rating on Boston Scientific, even though it trimmed its price target slightly to $70 from $71, signaling continued confidence in the company’s long-term outlook. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?
Positive Sentiment: Truist also kept a Buy rating, though it cut its price target to $64 from $85, suggesting analysts still see meaningful upside despite a more cautious valuation view. Benzinga
Positive Sentiment: The company announced plans for a $138 million medical device distribution facility in Indiana, which should expand operations and add 300 jobs, a sign of ongoing investment in growth and logistics capacity. Boston Scientific to open $138M medical device distribution facility in Indiana, adding 300 jobs
Neutral Sentiment: Boston Scientific’s last reported quarter was strong, with revenue of $5.20 billion and EPS of $0.80 beating expectations, but the company also cut guidance due to stronger competition in cardiac devices and slower Watchman growth, creating a mixed fundamental backdrop. How Investors May Respond To Boston Scientific (BSX) Strong Q1 Beat But Cut Guidance On Watchman Growth
Neutral Sentiment: Recent market commentary noted BSX has been trading above market averages on some sessions, but also lagging some peers, reflecting choppy investor sentiment rather than a clear trend. Boston Scientific Corp. stock underperforms Thursday when compared to competitors despite daily gains
Negative Sentiment: The repeated reductions in price targets from analysts, including Truist and Canaccord, suggest expectations have reset lower, which can weigh on sentiment even when ratings remain positive. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?

Insider Transactions at Boston Scientific

In related news, Director Edward J. Ludwig purchased 3,580 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the acquisition, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Cheryl Pegus purchased 1,770 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 9,800 shares of company stock valued at $554,012 over the last three months. 0.34% of the stock is currently owned by insiders.

Boston Scientific Price Performance

BSX stock opened at $48.66 on Friday. Boston Scientific Corporation has a 1 year low of $47.17 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The stock’s 50 day moving average price is $58.11 and its 200 day moving average price is $76.70. The firm has a market cap of $72.32 billion, a P/E ratio of 20.36, a PEG ratio of 0.91 and a beta of 0.56.

Boston Scientific (NYSE:BSX – Get Free Report) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the previous year, the firm posted $0.75 earnings per share. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 3.37 earnings per share for the current fiscal year.

Boston Scientific declared that its board has approved a stock buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.